1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades Infecciosas

Enfermedades Infecciosas

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD.

    CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use

    AIDS . 27(6): 907-918. Nº de citas: 13

    [doi:10.1097/QAD.0b013e32835cb766]

  • Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher HC, Kücherer C, Zangerle R, Kran AM, Porter K, CASCADE collaboration in EuroCoord.

    Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts

    CLINICAL INFECTIOUS DISEASES . 56(6): 888-897. Nº de citas: 69

    [doi:10.1093/cid/cis1000]

  • Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E.

    Risk of tuberculosis following HIV seroconversion in high-income countries

    Thorax . 68(3): 207-213. Nº de citas: 24

    [doi:10.1136/thoraxjnl-2012-201740]

  • van Griensven J, Diro E, Lopez-Velez R, Boelaert M, Lynen L, Zijlstra E, Dujardin JC, Hailu A.

    HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals

    LANCET INFECTIOUS DISEASES . 13(3): 251-259. Nº de citas: 29

    [doi:10.1016/S1473-3099(12)70348-1]

  • Casado JL, de la Calle C, del Palacio M, Perez-Elías MJ, Moreno A, Moreno S.

    Short Communication Lamivudine Plus a Boosted-Protease Inhibitor as Simplification Strategy in HIV-Infected Patients: Proof of Concept

    AIDS RESEARCH AND HUMAN RETROVIRUSES . 29(3): 588-591. Nº de citas: 6

    [doi:10.1089/aid.2012.0280]

  • Fortún J, Centella T, Martín-Dávila P, Lamas MJ, Pérez-Caballero C, Fernández-Pineda L, Otheo E, Cobo J, Navas E, Pintado V, Loza E, Moreno S.

    Infective endocarditis in congenital heart disease: a frequent community-acquired complication

    Infection . 41(1): 167-174. Nº de citas: 30

    [doi:10.1007/s15010-012-0326-6]

  • Lora-Tamayo J, Murillo O, Iribarren JA, Soriano A, Sánchez-Somolinos M, Baraia-Etxaburu JM, Rico A, Palomino J, Rodríguez-Pardo D, Horcajada JP, Benito N, Bahamonde A, Granados A, del Toro MD, Cobo J, Riera M, Ramos A, Jover-Sáenz A, Ariza J.

    A Large Multicenter Study of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Prosthetic Joint Infections Managed With Implant Retention

    CLINICAL INFECTIOUS DISEASES . 56(2): 182-194. Nº de citas: 217

    [doi:10.1093/cid/cis746]

  • Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Pérez-Elías MJ, Aguilera A, Caballero E, Soriano V, de Mendoza C.

    Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS . 27(1): 81-85. Nº de citas: 45

    [doi:10.1097/QAD.0b013e3283584500]

  • Serrano-Villar S, Gutiérrez C, Vallejo A, Hernández-Novoa B, Díaz L, Abad Fernández M, Madrid N, Dronda F, Zamora J, Muñoz-Fernández MÁ, Moreno S.

    The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression

    JOURNAL OF INFECTION . 66(1): 57-66. Nº de citas: 100

    [doi:10.1016/j.jinf.2012.09.013]

  • Mensa J, Soriano A, Llinares P, Barberán J, Montejo M, Salavert M, Alvarez-Rocha L, Maseda E, Moreno A, Pasquau J, Gómez J, Parra J, Candel J, Azanza JR, García JE, Marco F, Soy D, Grau S, Arias J, Fortún J, de Alarcón CA, Picazo J.

    Guía de tratamiento antimicrobiano de la infección por Staphylococcus aureus.

    REVISTA ESPANOLA DE QUIMIOTERAPIA . 26 Suppl 1: 1-84.

  • Jarrin I, Hernández-Novoa B, Alejos B, Riera M, Navarro G, Bernardino JI, Rivero M, del Amo J, Moreno S.

    Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010

    ANTIVIRAL THERAPY . 18(2): 161-170. Nº de citas: 12

    [doi:10.3851/IMP2287]

  • Casado JL, de Los Santos I, Del Palacio M, García-Fraile L, Pérez-Elías MJ, Sanz J, Moreno S.

    Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.

    HIV CLINICAL TRIALS . 14(1): 1-9.

    [doi:10.1310/hct1401-1]

  • Gutiérrez C, Hernández-Novoa B, Pérez-Elías MJ, Moreno AM, Holguín A, Dronda F, Casado JL, Moreno S.

    Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.

    HIV CLINICAL TRIALS . 14(1): 10-16.

    [doi:10.1310/hct1401-10]

  • May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA.

    Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics

    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY . 41(6): 1807-1820. Nº de citas: 31

    [doi:10.1093/ije/dys164]

  • Len O, Rodríguez-Pardo D, Gavaldà J, Aguado JM, Blanes M, Borrell N, Bou G, Carratalà J, Cisneros JM, Fortún J, Gurguí M, Montejo M, Cervera C, Muñoz P, Asensio A, Torre-Cisneros J, Pahissa A.

    Outcome of Clostridium difficile-associated disease in solid organ transplant recipients: a prospective and multicentre cohort study

    TRANSPLANT INTERNATIONAL . 25(12): 1275-1281. Nº de citas: 32

    [doi:10.1111/j.1432-2277.2012.01568.x]

  • Vidal E, Torre-Cisneros J, Blanes M, Montejo M, Cervera C, Aguado JM, Len O, Carratalá J, Cordero E, Bou G, Muñoz P, Ramos A, Gurguí M, Borrell N, Fortún J.

    Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort

    TRANSPLANT INFECTIOUS DISEASE . 14(6): 595-603. Nº de citas: 98

    [doi:10.1111/j.1399-3062.2012.00744.x]

  • Podzamczer D, Martínez E, Domingo P, Ferrer E, Viciana P, Curto J, Pérez-Elías MJ, Ocampo A, Santos I, Knobel H, Estrada V, Negredo E, Segura F, Portilla J, Ribera E, Galindo J, Antela A, Carmena J, Castaño M.

    Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study

    CURRENT HIV RESEARCH . 10(8): 673-678. Nº de citas: 3

    [doi:10.2174/157016212803901428]

  • Martínez E, D'Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, Berenguer J, Domingo P, Moreno X, Perez I, Pich J, Gatell JM, SPIRAL Trial Group.

    Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

    AIDS . 26(18): 2315-2326. Nº de citas: 99

    [doi:10.1097/QAD.0b013e328359f29c]